5-Hydroxytryptamine and 5-Hydroxytryptamine-3 Receptor Antagonists

Reference

• Rapport M M, Green A A, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterisation. J Biol Chem 1948; 176: 1243–1251
   PubMed Web of Science ®Google Scholar
• Erspamer V, Asero B. Isolation of enteramine from extracts of posterior salivary glands of Octopus vulgaris and of Discoglossus pictus skin. J Biol Chem 1953; 200: 311–318
   PubMed Web of Science ®Google Scholar
• Gronstad K O, de Magistris L, Dahlström A, et al. The effects of vagal stimulation on endoluminal release of serotonin and substance P into the feline small intestine. Scand J Gastroenterol 1985; 20: 163–169
   PubMed Web of Science ®Google Scholar
• Bülbring E, Crema A. The release 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J Physiol (Lond) 1959; 146: 381–407
   Google Scholar
• Beubler E, Horina G. 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology 1990; 99: 83–89
   PubMed Web of Science ®Google Scholar
• Gershon M D, Drakontides A B, Ross LL. Serotonin: synthesis and release from the myenteric plexus of the mouse intestine. Science 1965; 149: 197–199
   PubMed Web of Science ®Google Scholar
• Gershon M D, Sherman DL. Noradrenergic innervation of serotonergic neurons in the myenteric plexus. J Comp Neurol 1987; 259: 193–210
   PubMed Web of Science ®Google Scholar
• Ferrara A, Zinner M J, Jaffe BM. Intraluminal release of serotonin, substance P, and gastrin in the canine small intestine. Dig Dis Sci 1987; 32: 289–294
   PubMed Web of Science ®Google Scholar
• Bülbring E, Crema A. Observations concerning the action of 5-hydroxytryptamine on the peristaltic reflex. Br J Pharmacol 1985; 13: 444–457
   Google Scholar
• Gershon M D, Tamir H. Release of endogenous 5-hydroxytryptamine from resting and stimulated enteric neurons. Neuroscience 1981; 6: 2277–2286
   PubMed Web of Science ®Google Scholar
• Davidson H I, Pilot MA. Does endogenous neuronal 5-hydroxytryptamine influence canine intestinal motility?. J Physiol (Lond) 1986; 376: 49, P
   Google Scholar
• Bülbring E, Gershon MD. 5-hydroxytryptamine participation in the vagal inhibitory innervation of the stomach. J Physiol (Lond) 1967; 192: 823–846
   Google Scholar
• Rattan S, Goyal RK. Evidence of 5-HT participation in vagal inhibitory pathway to opposum LES. Am J Physiol 1978; 234: E273–276
   Google Scholar
• Gaddum J H, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957; 12: 323–328
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. 5-hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterisation. Trends Neurosci 1988; 11: 496–500
   PubMed Web of Science ®Google Scholar
• Costall B, Naylor RJ. 5-hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990; 25: 769–787
   PubMed Web of Science ®Google Scholar
• Costall B, Cunning S J, Tyers MB. The effect of GR38032F novel 5-HT3 receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol 1987; 91: 263–264
   PubMed Web of Science ®Google Scholar
• Gore S, Gilmore I T, Haigh C G, Brownless S M, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F) a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4: 139–144
   PubMed Web of Science ®Google Scholar
• Nielson O H, Hvid-Jacobsen K, Lund P, Langholz E. Gastric emptying and subjective symptoms of nausea: Lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990; 46: 89–96
   PubMed Web of Science ®Google Scholar
• Akkermans L MA, Vos A, Hoekstra A, Roelofs J MM, Horowitz M. Effect of ICS 205–930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 1988; 29: 1249–1252
   PubMed Web of Science ®Google Scholar
• Brown N J, Rumsey R DE, Read NW. The effect of 5-HT3 receptor antagonist on the ileal brake mechanism in the rat. Gut 1990; 31: A1204
   Web of Science ®Google Scholar
• Talley N J, Phillips S F, Haddad A, et al. Effect of selective 5-HT3 antagonist (GR38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34: 1511–1515
   PubMed Web of Science ®Google Scholar
• Meleagros L, Kreymann B, Ghatei M A, Bloom SR. Mouth-to-caecum transit time in man is reduced by novel serotonin M-receptor antagonist. Gut 1987; 28: A1373
   Web of Science ®Google Scholar
• Talley N J, Phillips S F, Haddad A, et al. GR 38032F (Ondansetron), a selective 5-HT3 receptor antagonist, slow colonic transit in healthy man. Dig Dis Sci 1990; 35: 477–480
   PubMed Web of Science ®Google Scholar
• Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT, receptor antagonist in patients with irritable bowel syndrome (IBS). Gut 1990; 31: A1174
   Web of Science ®Google Scholar
• Dumuis A, Bouhelal R, Sebben M, Bockaert J. A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonist by ICS 205–930. Eur J Pharmacol 1988; 146: 187–188
   PubMed Web of Science ®Google Scholar
• Cubeddu L X, Hoffman I S, Fuenmayor N T, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–816
   PubMed Web of Science ®Google Scholar
• Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
   PubMed Web of Science ®Google Scholar
• Larijani G E, Gratz I, Jacobi A G, et al. Randomized, double-blind comparison of ondansetron and placebo in the treatment of post-operative nausea and vomiting. Anesthesiology 1990; 73: A33
   PubMed Web of Science ®Google Scholar
• McKenzie R, Odell S, Rudy S NA, Joslyn AF. Ondansetron, a selective serotonin type 3 (5-HT3) antagonist reduces nausea and vomiting in females following major gynecologic surgery. Anesthesiology 1990; 73: A739
   PubMed Web of Science ®Google Scholar
• Sanger G J, King FD. From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. Drug Design Deliv 1988; 3: 273–295
   PubMedGoogle Scholar
• Robertson C S, Ledingham S J, Cooper S M, Evans DF. A double-blind dose ranging study of BRL 24924 and metoclopramide on lower oesophageal sphincter pressure in healthy volunteers. J Clin Pharmacol 1989; 28: 323–327
   Web of Science ®Google Scholar
• Burke T A, Sanger GJ. Regionally selective cholinergic stimulation by BRL24924 in the human isolated gut. Br J Clin Pharmacol 1988; 261–265
   PubMed Web of Science ®Google Scholar
• Steadman C J, Talley N J, Phillips S F, Mulvihill C. Trial of serotonin type 3 (5-HT3) receptor antagonist ondansetron (GR 38032F) in diarrhea predominant irritable bowel syndrome (IBS). Gastroenterology pt 2, 1990; 98: A394
   Google Scholar
• Donowitz M, Asarkof N, Pike G. Calcium dependence of serotonin-induced changes in rabbit ileal electrolyte transport. J Clin Invest 1980; 66: 341–352
   PubMed Web of Science ®Google Scholar
• Beubler E, Bukhave K, Rask-Madsen J. Significance of calcium for the prostaglandin E2-mediated secretory response to 5-hydroxytryptamine in the small intestine of the rat in vivo. Gastroenterology 1986; 90: 1972–1977
   PubMed Web of Science ®Google Scholar
• Berridge M J, Irvine RF. Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315–321
   PubMed Web of Science ®Google Scholar
• Coupe M, Levi S, Ellis M, et al. Therapy for symptoms in the carcinoid syndrome. Q J Med 1989; 73: 1021–1036
   PubMedGoogle Scholar
• Anderson J V, Coupe M O, Morris J A, Hodgson H JF, Bloom SR. Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist. Br Med J 1987; 294: 1129
   PubMed Web of Science ®Google Scholar
• Nilsson O, Cassuto J, Larsson P A, et al. 5-Hydroxytryptamine and cholera secretion: a histochemical and physiological study in cats. Gut 1983; 24: 542–548
   PubMed Web of Science ®Google Scholar
• Beubler E, Kollar G, Saria A, Bukhave K, Rask-Madsen J. Involvement of 5-hydroxytryptamine, prostaglandin E2 and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of rat in vivo. Gastroenterology 1989; 96: 368–376
   PubMed Web of Science ®Google Scholar
• Beubler K, Horina G. 5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat. Gastroenterology 1990; 99: 83–89
   PubMed Web of Science ®Google Scholar
• Buchheit K-H. Inhibition of cholera toxin-induced intestinal secretion by the 5-HT3 receptor antagonist ICS 205–930. Naunyn-Schmiedebergs Arch Pharmacol 1989; 339: 704–705
   PubMed Web of Science ®Google Scholar
• Munck L K, Mertz-Nielsen A, Westh H, Bukhave K, Beubler E, Rask-Madsen J. Prostaglandin E2 is a mediator of 5-hydroxytryptamine induced water and electrolyte secretion in the human jejunum. Gut 1988; 29: 1337–1341
   PubMed Web of Science ®Google Scholar
• Thillainayagam A V, Dias J A, Schrigi-Degen A, et al. A potential role for 5-hydroxytryptamine (5-HT) in mediating cholera toxin (CT) induced secretion in man. Gut 1991, In press
   PubMed Web of Science ®Google Scholar
• Gintzler AR. Serotonin participation in gut withdrawal from opiates. J Pharmacol Exp Ther 1979; 211: 7–12
   PubMed Web of Science ®Google Scholar
• Beubler E, Bukhave K, Rask-Madsen J. Colonic secretion mediated by prostaglandin E2 and 5-hydroxytryptamine may contribute to diarrhoea due to morphine withdrawal in the rat. Gastroenterology 1984; 87: 1042–1048
   PubMed Web of Science ®Google Scholar